دانلود رایگان مقاله بازی قدرت نهادی در سیستم های نوآوری: مورد Herceptin

abstract

New technologies must be accompanied by institutional change. Innovative actors therefore need to do institutional work or take a role as an institutional entrepreneur in order to shape the institutions in the best interests of their technology. However, the literature on system building and on institutional entrepreneurship have little overlap. The goal of this paper is to bridge these two bodies of literature to gain additional insights into how institutional change evolves in a technological innovation system. We show how the pharmaceutical firm Roche acted as a powerful institutional entrepreneur by influencing the health-care system in England to create a market for the personalized cancer drug Herceptin®. We demonstrate thatinstitutional change can be preceded by a range ofinnovation system-building activities that are not directly intended to bring aboutinstitutional change but are required in order for institutional change to take place. Through this case study, we show how the system-building and institutional change literature can complement each other.

6. Conclusions

This study contributes to our understanding of actor strategies involved in system building in a technological innovation system (TIS) and, more specifically, in institutional change that creates a more favorable environment for the adoption of an emerging biomedical technology. It analyzed how system builders deal with institutions that are not beneficial to their technology and activities they undertake in order to shape the institutional structures that are important for the innovation system.